ATLAS Trial
Cross-source consensus on ATLAS Trial from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Dosage & preparation
Evidence quality
Highlighted claims
- The ATLAS trial tested Urolithin A supplementation in sedentary adults aged 40–64 with age-related physical-function decline. — Urolithin A: A Postbiotic for Mitochondrial Health and Longevity
- The ATLAS trial compared 500 mg and 1,000 mg daily Urolithin A against placebo for four months. — Urolithin A: A Postbiotic for Mitochondrial Health and Longevity
- The 1,000 mg group improved peak VO2 max and six-minute walk performance. — Urolithin A: A Postbiotic for Mitochondrial Health and Longevity
- The 500 mg Urolithin A group improved hamstring strength by 12% from baseline. — Urolithin A: A Postbiotic for Mitochondrial Health and Longevity